☆ 4.5 Article

Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy

EUROPEAN JOURNAL OF RADIOLOGY (2024)

Related references

Note: Only part of the references are listed.

Article Radiology, Nuclear Medicine & Medical Imaging

Neoadjuvant immune-checkpoint inhibitors in lung cancer- a primer for radiologists

Daria Kifjak et al.

Summary: The introduction of neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy has revolutionized the treatment of early-stage lung cancer, leading to high rates of complete pathologic response and improved clinical outcomes. Diagnostic imaging plays a crucial role in evaluating treatment response, monitoring adverse events, and aiding in optimal treatment and diagnostic workup of resected tumor samples for surgeons and pathologists. Radiologists should possess knowledge of the strengths and limitations of diagnostic imaging in this context to provide valuable input in multidisciplinary team decisions.

EUROPEAN JOURNAL OF RADIOLOGY (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab

Florian Eude et al.

Summary: This study evaluates the prognostic value of total tumour volume (TTV) by adding necrotic tumour volume (NTV) to metabolic tumour volume (MTV) in immunotherapy for non-small cell lung cancer (NSCLC) patients. The results show that TTV has a higher predictive value in prognostic assessment.

ANNALS OF NUCLEAR MEDICINE (2022)

Add to Collection

Article Oncology

Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy

Cristina Julian et al.

Summary: This retrospective cohort study aimed to investigate prognostic factors of overall survival in patients with advanced non-small cell lung cancer and develop a novel prognostic model. Factors such as low albumin and chloride levels, Eastern Cooperative Oncology Group performance status score, and high alkaline phosphatase and white blood cell levels were identified as risk-increasing prognostic factors. The model's performance was validated using data from the OAK trial, showing a c-index of 0.65 for the OAK trial validation cohort and 0.67 for the real-world data cohort.

CANCER REPORTS (2022)

Add to Collection

Article Oncology

Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy

Chang Gon Kim et al.

Summary: The study evaluated the effectiveness of PET/CT variables and NLR as predictive biomarkers for clinical outcomes in patients with advanced NSCLC receiving pembrolizumab and chemotherapy as a first-line treatment. The results showed these markers were useful in predicting treatment response, PFS, and overall survival, suggesting their potential as effective markers for combined PD-1 blockade and chemotherapy in NSCLC patients.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression

Karolien Vekens et al.

Summary: This study evaluated the usefulness of F-18-FDG PET/CT-derived parameters in predicting response and survival after PD-1 blocking immunotherapy in advanced NSCLC patients with high PD-L1 expression. The results indicated that baseline metabolic tumor volume did not impact clinical response and survival, while reduction of tumor volume after 8 to 9 weeks of treatment was a better predictor for prolonged survival.

CLINICAL LUNG CANCER (2021)

Add to Collection

Article Oncology

First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes

David Lang et al.

Summary: PET/CT-derived biomarkers, such as MTV, can assist in prognostic evaluation and treatment decision-making in NSCLC patients receiving first-line ICI in combination with chemotherapy, with higher MTV associated with poorer PFS/OS outcomes.

CANCERS (2021)

Add to Collection

Article Medicine, General & Internal

Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors

Angelo Castello et al.

Summary: The study found that the use of antibiotics is associated with poorer treatment response, PFS, and higher metabolic tumor burden in NSCLC patients treated with immune checkpoint inhibitors.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Review Oncology

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

Virginia Liberini et al.

Summary: Lung cancer, especially non-small cell lung cancer, remains a primary cause of cancer-related death. New therapeutic approaches, including immunotherapy, have shown significant improvement in patient survival and quality of life. However, the identification of predictive biomarkers is crucial to determine which patients will benefit most from immunotherapy-based treatments.

CANCERS (2021)

Add to Collection

Review Medicine, General & Internal

The association between CD8+tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis

Feng Li et al.

Summary: The study found that high CD8+ TILs were significantly associated with better overall survival, progression-free survival, and objective response rate in cancer patients treated with ICIs. High CD8+ TILs predicted treatment outcomes across different cancers and treatment types.

ECLINICALMEDICINE (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors

Romain-David Seban et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)

Add to Collection

Article Medicine, Research & Experimental

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma

Dina Guo et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Oncology

Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors

Angelo Castello et al.

CANCERS (2020)

Add to Collection

Article Medicine, General & Internal

Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma

Lucian Beer et al.

WIENER KLINISCHE WOCHENSCHRIFT (2020)

Add to Collection

Article Medicine, General & Internal

Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer

Kosuke Hashimoto et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Oncology

Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study

David Chardin et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Oncology

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

Romain-David Seban et al.

CANCERS (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer

Romain-David Seban et al.

ANNALS OF NUCLEAR MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%

Ou Yamaguchi et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Oncology

[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab

Damijan Valentinuzzi et al.

RADIOLOGY AND ONCOLOGY (2020)

Add to Collection

Review Immunology

Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives

Sun Min Lim et al.

IMMUNE NETWORK (2020)

Add to Collection

Article Oncology

The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study

T. Karantanos et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2019)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer

Lucian Beer et al.

CLINICAL NUCLEAR MEDICINE (2019)

Add to Collection

Article Oncology

Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors

Tao Jiang et al.

LUNG CANCER (2019)

Add to Collection

Article Oncology

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers

Mingjia Li et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer

Norimitsu Kasahara et al.

LUNG CANCER (2019)

Add to Collection

Letter Radiology, Nuclear Medicine & Medical Imaging

Is it time to change our vision of tumor metabolism prior to immunotherapy?

Fabio Grizzi et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)

Add to Collection

Article Oncology

Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer

Amanda Jane Williams Gibson et al.

MEDICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

Aixa E. Soyano et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

Add to Collection

Review Oncology

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Mizuki Nishino et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

Add to Collection

Review Oncology

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)

J. M. Kim et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Review Oncology

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Geoffrey T. Gibney et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Oncology

Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study

L. E. Hendriks et al.

EUROPEAN JOURNAL OF CANCER (2015)

Add to Collection

Article Biochemistry & Molecular Biology

The prognostic landscape of genes and infiltrating immune cells across human cancers

Andrew J. Gentles et al.

NATURE MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Julie Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Respiratory System

The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology

JF Vansteenkiste et al.

EUROPEAN RESPIRATORY JOURNAL (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.